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Abstract: P2X receptors are Ca2+-permeable cationic channels in the cell membranes, 
where they play an important role in mediating a diversity of physiological and 
pathophysiological functions of extracellular ATP. Mammalian cells express seven P2X 
receptor genes. Single nucleotide polymorphisms (SNPs) are widespread in the P2RX 
genes encoding the human P2X receptors, particularly the human P2X7 receptor.  
This article will provide an overview of the non-synonymous SNPs (NS-SNPs) that have 
been associated with or implicated in altering the susceptibility to pathologies or disease 
conditions, and discuss the consequences of the mutations resulting from such NS-SNPs on 
the receptor functions. Disease-associated NS-SNPs in the P2RX genes have been valuable 
in understanding the disease etiology and the receptor function, and are promising as 
biomarkers to be used for the diagnosis and development of stratified therapeutics. 
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1. Introduction 
Adenosine triphosphate (ATP) is best known as an intracellular energy supplier for a wide range of 
activities inside the cell. However, ATP is also released into the extracellular milieu where it acts as  
a signalling molecule. It was first shown in a seminal study that ATP released from sensory nerves 
caused vasodilation [1]. The theory of purinergic signalling was posited in 1972 [2] but remained 
controversial until molecular cloning of the genes encoding the receptors for extracellular ATP in the 
1990s [3–6]. It is now firmly established that two structurally and functionally distinctive families of 
P2 purinergic receptors in the cell membranes mediate intracellular signalling evoked by extracellular 
ATP; ligand-gated ion channel P2X receptors and G-protein-coupled P2Y receptors [7]. 
Mammalian cells express seven genes encoding seven P2X receptor subunits, P2X1–P2X7 [8]. 
These subunits are capable of forming homomeric receptors on their own, with the exception of the 
P2X6 subunit, or heteromeric receptors, with P2X1/2, P2X1/4, P2X1/5, P2X2/3, P2X2/5, P2X2/6 and 
P2X4/6 receptors being defined so far [9]. P2X receptors are expressed in many tissues and cells, 
where they are important in mediating a diversity of physiological processes from neurotransmission, 
muscle contraction and hearing to immune responses. P2X receptors function as Ca2+-permeable 
cationic channels that open in response to brief receptor activation. Prolonged activation of many of 
the P2X receptors, most saliently the P2X7 receptor, can induce formation of large pores that confer 
permeability of the cell membranes to much larger cations and fluorescent dyes [8]. The cellular 
distribution, pharmacological properties, and physiological and pathophysiological functions of  
the P2X receptors have been extensively discussed in several recent reviews [9–13]. The P2RX genes 
encoding the human P2X receptors, particularly the human P2X7 receptor, are highly polymorphic and 
contain a large set of single nucleotide polymorphisms (SNPs). Genetic association studies support 
non-synonymous SNPs (NS-SNPs) in the P2RX genes as an important genetic factor that alters  
the susceptibility of individuals to various disease conditions. Characterisation of the mutations in  
P2X receptors resulting from NS-SNPs have shed light on general and receptor-specific  
structure-function relationships of these receptors [9]. Furthermore, by combining these approaches, 
studies of disease-associated NS-SNPs have provided novel insights into disease mechanisms  
(e.g., [14]). In this short review, we will discuss the NS-SNPs in the P2RX genes, focusing on those 
which are associated with or implicated in various pathologies. We will give a brief introduction of the 
context and describe the studies that support association of NS-SNPs with particular disease(s).  
We will also discuss the consequences of such NS-SNP mutations on receptor function in order to 
facilitate a better understanding of the disease mechanisms and structure-function relationships of P2X 
receptors. Disease-associated NS-SNPs in the P2RX genes are promising as biomarkers to be used for 
the diagnosis and development of stratified therapeutics. 
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2. Non-Synonymous Single Nucleotide Polymorphisms (NS-SNPs) in the P2RX Genes and  
Disease Association 
2.1. NS-SNPs in the P2RX2 Gene Increase Susceptibility to Hearing Loss 
The human P2RX2 gene has a chromosomal location of 12q24.33 and is composed of 11 exons [15]. 
Expression of the P2X2 receptor is found in the cochlea of the inner ear, particularly in spiral ganglion 
neurons, epithelial cells in Reissner’s membrane, and hair cell stereocilia in the organ of Corti [16–18]. 
Furthermore, there is evidence to suggest that noise up-regulates P2X2 receptor expression in the 
cochlea [19]. Such observations have led to numerous investigations into the role of the P2X2 receptor 
in regulating multiple processes in hearing, including auditory neurotransmission [18,20], outer hair 
cell electromotility [21], K+ recycling [22,23], and control of inner ear gap junctions [22]. Overall, 
these studies have provided clear evidence to support a critical role for the P2X2 receptor in maintaining 
normal hearing. Consistently, P2X2-deficient mice manifested severe progressive hearing loss and 
high-frequency hearing loss as a result of exposure to continuous moderate noise in young  
adulthood [24,25]. 
Noise-induced hearing loss and age-related hearing loss are the two major forms of hearing loss in 
humans. DFNA41 is an autosomal dominant and non-syndromic form of deafness which presents as 
bilateral and symmetrical post-lingual sensorineural hearing loss, often with high frequency  
tinnitus occurring simultaneously [26]. The age of DFNA41 onset ranges from 12 to 20 years and is 
progressive throughout the sufferer’s life time, resulting in hearing loss across all frequencies.  
The gene(s) responsible for the hearing loss have been mapped to a locus between the marker 
D12S1609 and 12qter [26]. A rare heterozygous allele containing 178G>T in the P2RX2 gene has 
recently been discovered through linkage analysis of genomic DNA from DFNA41 members in two 
unrelated Chinese families, but not in a large group of control subjects [25]. Moreover, this NS-SNP, 
resulting in the substitution of valine with leucine at position 60 (V60L) in the human P2X2 receptor, 
confers loss of receptor function [25]. The members of these two families who were heterozygous for 
the 178G>T or carried the V60L mutation exhibited significantly greater high-frequency hearing loss 
following noise exposure in young adulthood [25]. Another recent linkage analysis study of an Italian 
family has identified a distinctive NS-SNP, 1057G>C [27]. This NS-SNP changes glycine at position 
353 to arginine (G353R) in the human P2X2 receptor. 
2.2. NS-SNP in the P2RX4 Gene 
2.2.1. 1248A>G Is Associated with High Pulse Pressure 
The human P2RX4 gene is located on chromosome 12q24.31 [28,29] and has 12 exons. Expression 
of the P2X4 receptor has been documented in endothelial cells. Activation of the P2X4 receptor induced by 
ATP, released from vascular endothelial cells in response to fluid shear stress, can lead to extracellular  
Ca2+ influx. This subsequently induces the generation of nitric oxide and vessel dilation [30–32].  
Genetic deletion of the P2X4 receptor in mice impaired blood flow-dependent control of vascular tone 
and loss of adaptive vascular remodelling (i.e., decrease in vessel size in response to a chronic decrease 
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in blood flow) [33]. These studies have underscored a critical role for the P2X4 receptor in the 
mechanisms that enable vascular remodelling in response to changes in blood flow. 
Pulse pressure, the difference between systolic and diastolic blood pressures, is dependent on the 
elastic properties of large arteries as well as cardiac stroke volume, and has gained increasing 
recognition as an important and independent indicator of morbidity and mortality in cardiovascular 
diseases. A recent study has genotyped two Australian cohorts composed of 430 and 2874 subjects 
respectively and identified the 1248A>G polymorphism (rs28360472) as a potential risk factor for 
high pulse pressure [34]. This NS-SNP results in the substitution of tyrosine at position 315 with 
cysteine in the human P2X4 receptor, which impairs receptor function. Analysis of the second cohort 
suggests an association between the 1248A>G polymorphism and high pulse pressure [34]. 
2.2.2. 1248A>G Increases Susceptibility to Age-Related Macular Degeneration (AMD) 
Macular degeneration is a major cause of blindness amongst the elderly [35]. The pathogenesis of 
age-related macular degeneration (AMD) includes genetic changes which compromise the innate 
immunity required for clearance of debris in the retina. The P2X4 receptor, together with the P2X7 
receptor, which will be introduced in the next section, is found in microglia and macrophages in the 
central nervous system (CNS) and in the eye [36,37]. A recent study has investigated the 1248A>G 
polymorphism in the P2RX4 gene and eleven NS-SNPs in the P2RX7 gene in a cohort of  
744 Caucasian AMD patients and 557 control subjects [36]. This study found an association of  
the 1248A>G polymorphism in the P2RX4 gene, but none of the NS-SNPs in the P2RX7 gene, with 
increased susceptibility to AMD. The P2X7 receptor is known to exhibit significant scavenger receptor 
activity [38]. P2X7 receptor-mediated phagocytosis was strongly suppressed in cells co-expressing  
the P2X7 receptor with the P2X4 receptor carrying the Y315C mutation [36], supporting the notion 
that a functional partnership between these two receptors is important in maintaining the scavenger 
function of macrophages and microglia in the eye. 
2.3. NS-SNPs in the P2RX7 Gene 
The human P2RX7 gene shares approximately the same chromosomal location as the P2RX4 gene, 
within 130 kb based on radiation hybrid mapping, and contains 13 exons [28]. The P2X7 receptor is 
widely expressed in immune cells such as monocytes, macrophages, mast cells, lymphocytes, 
leukocytes, and dendritic cells. It is important in underpinning the role of extracellular ATP in immune 
responses, including the production of pro-inflammatory cytokines, such as interleukin (IL)-1β, and 
elimination of dead cells and intracellular pathogens, and also in stimulating cell proliferation and cell 
death [39]. The P2X7 receptor is also expressed by microglia, astrocytes and oligodendrocytes in the 
CNS and plays a role in glia-neuron interactions via mediating the release of neurotransmitters as well 
as the generation of IL-1β from microglia [11,39]. The P2X7 receptor present on satellite glial cells of  
the dorsal root ganglions (DRG) in the peripheral nervous system (PNS) has a similar role in mediating 
ATP release. Furthermore, the P2X7 receptor is found on bone cells. In osteoblasts the receptor is 
engaged in the activation of downstream extracellular signal-regulated kinase as a result of fluid flow 
and stimulation of mineralisation [40–43]. In osteoclasts the P2X7 receptor has been implicated in  
the formation of multinucleated cells, apoptosis, NF-κB activation, and it is required for intercellular 
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Ca2+ signalling between osteoclasts and osteoblasts [44]. In P2X7-KO mice, the trabecular bone 
resorption in the tibias was increased, but the overall and cortical bone content, periosteal 
circumference in the femurs, and periosteal bone formation were reduced [45] and the effect of 
mechanical loading on periosteal bone formation was also attenuated [42]. These findings support  
a crucial role for the P2X7 receptor in bone formation, metabolism and remodelling. 
A number of studies of SNPs in the P2RX7 gene have been carried out over a period of more than  
a decade in order to examine a potential role of the human P2X7 receptor in the aetiology of a variety  
of clinical conditions, including chronic lymphocytic leukaemia (CCL) [46–51], affective mood  
disorders [52–55], multiple sclerosis [56], chronic pain [14], systemic lupus erythematosus, rheumatoid 
arthritis [57–59], childhood febrile seizure [60], ischemic stroke, ischemic heart disease [61], 
tuberculosis [62–66], sepsis [67], toxoplasmosis [68,69], osteoporosis, and bone fracture [70–74]. 
Table 1 provides a brief summary of the NS-SNPs that have been associated with or implicated in 
altering susceptibility to particular disease condition(s). One point of note is that the 1513A>C 
polymorphism was proposed in earlier studies to be associated with CLL [46,47], but such association 
has not been supported by subsequent studies [48–51]. In several other cases the supporting evidence 
remains limited. In the following section we will discuss the studies that support association of 
NS-SNPs in the P2RX7 gene with disease(s). 
2.3.1. 1405A>G and 1068G>A Are Implicated in Susceptibility to Affective Mood Disorders 
Affective mood disorders, including bipolar disorder (BD), major depressive disorder (MDD) and 
anxiety disorder (AD), define a large group of common depression conditions, all characterized by 
consistent and pervasive alterations in mood that change thoughts, emotions and behaviours and 
thereby result in social impairments [75–79]. The P2RX7 gene has been identified as a locus of 
susceptibility to affective mood disorders [80]. Several groups have conducted genetic association 
analysis of SNPs in the P2RX7 gene in order to probe the role of the human P2X7 receptor in the 
pathogenesis of affective mood disorders. The first two studies were reported in 2006, one examining  
a cohort consisting of 231 Canadian BD patients (182 type-I and 31 type-II) and 214 control subjects [52], 
and the other study a cohort comprising 1000 German Caucasian patients diagnosed with MDD and 
1029 control subjects [53]. Both studies have revealed an association of the 1405A>G polymorphism 
for the Q460R mutation with BD [52] and MDD [53]. A subsequent study of 604 BD patients and  
560 control subjects with UK and Irish background has confirmed this association [55]. This study, 
when combined with the previous studies by Barden et al. [52] and Lucae et al. [53], has found  
an even more robust association with affective mood disorders. Another study analysing 171 
Hungarian patients with MDD, type-I and type-II BD and 178 control subjects also supports the 
association of the 1405A>G polymorphism with affective mood disorders [81]. However, no 
significant association with the 1405A>G polymorphism was observed in a UK cohort of 687 patients 
with type-I BD, 1036 patients with unipolar recurrent major depression and 1204 control subjects [82] 
and also in a cohort of 1445 type-I BD patients and 2006 control subjects from four Central and 
Eastern European countries (Germany, Poland, Romania, and Russia) [83]. A meta-analysis study of 
6962 patients and 9262 control subjects from 13 different studies deposited in various databases has 
also concluded no association of the 1405A>G polymorphism with affective mood disorders overall, 
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but has found significant association in family-based cohorts [84]. A study examining a cohort of  
179 Caucasian patients with AD and syndromal panic attacks and 462 control subjects has shown a 
trend for association of the 1068G>A polymorphism, encoding the gain-of-function A348T mutation, 
with AD [54]. However, several recent large-scale genome-wide association studies have failed to 
identify P2RX7 as a locus of susceptibility to BD [85–87]. Future studies of large and clearly annotated 
samples are required to clarify or validate the association of these NS-SNPs in the P2RX7 gene with 
affective mood disorders. 
2.3.2. 370T>C and 489C>T Increase Susceptibility to Multiple Sclerosis (MS) 
Multiple sclerosis (MS) is a CNS neurodegenerative disease, characterized by white matter lesions 
with demyelination, inflammation and axonal degeneration [88]. Increased P2X7 expression has been 
found in lesion sites in the spinal cord and brain of MS patients [89,90]. A study, using experimental 
autoimmune encephalomyelitis of mice, a rodent model of human MS, has shown that inhibition of  
the P2X7 receptor using selective antagonists can reduce demyelination as well as improving  
MS-associated neurological deficits, thus providing strong evidence to support a role for the P2X7 
receptor in the pathogenesis of MS [91]. A recent study has examined a cohort of 734 MS Spanish 
patients and found that the 370T>C and 489C>T polymorphisms are prevalent in these patients and 
associated with an increased susceptibility to MS [56]. These two NS-SNPs introduce gain-of-function 
A76V and H155Y mutations in the human P2X7 receptor. 
2.3.3. 489C>T and 835G>A Alter Chronic Pain Sensitivity 
It has long been known that extracellular ATP is nociceptive. The P2X2/3 receptor, which is 
exclusively expressed in DRG neurons, mediates ATP-induced pain and inflammatory and neuropathic 
pain [13]. The P2X4 receptor also contributes to chronic neuropathic and inflammatory pain with its 
up-regulated expression in the activated spinal microglia following peripheral nerve injury being 
critical in the development of neuropathic pain [13]. Moreover, the P2X4 receptor in tissue-residing 
macrophages is critically involved for inflammatory pain [13]. As mentioned above, the P2X7 receptor 
mediates ATP-induced IL-1β release from immune cells and glia-neuron interactions and therefore  
plays an important role in chronic inflammatory and neuropathic pain. Consistently, studies using 
rodent models have shown that P2X7 deficiency or pharmacological inhibition of the P2X7 receptor 
can attenuate neuropathic and inflammatory pain [92,93]. It is worth mentioning that the P2X7 
receptor expressed in DRG satellite glial cells plays a role in attenuating pain. This is achieved  
by constituting an inhibitory mechanism along with the P2Y1 receptor in DRG neurons in order to  
down-regulate P2X3 protein surface expression on DRG neurons, thereby reducing the pain signalling 
mediated by P2X receptors containing the P2X3 subunit [94]. 
A recent genome-wide study of SNPs in the genes encoding the mouse and human P2X7 
receptors has provided further support for a critical role of the P2X7 receptor in chronic pain [14].  
More importantly, detailed analysis of the effect of a pain-related NS-SNP on the functional properties 
of the P2X7 receptor has shed light on the disease mechanism at the receptor level. This study first 
assessed a number of SNPs in several genes in relation to the severity of nerve injury-induced tactile 
hypersensitivity or mechanical allodynia in 18 strains of mice. One of the NS-SNPs identified in the 
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mouse p2rx7 gene, which was strongly associated with altered sensitivity to chronic neuropathic pain, 
introduces P451L mutation in the C-terminal tail of the mouse P2X7 receptor. Mice expressing  
the Leu451-containing P2X7 receptor were substantially less sensitive to neuropathic pain than mice 
expressing the Pro451-containing P2X7 receptor. Further functional characterizations of the P2X7 
receptors expressed in macrophage cells from these mice indicate that the P451L mutation strongly 
impairs the large pore-forming functionality, without altering ion channel function. These results 
suggest that the ability of the P2X7 receptor to induce or form large pores has a critical role in 
determining the sensitivity to chronic neuropathic pain. The same study also examined several SNPs in 
the human P2RX7 gene in two different cohorts of patients with chronic inflammatory pain [14]. In the 
first cohort composed of over 300 women with breast surgery, approximately half developed chronic 
pain following the procedure; the 489C>T polymorphism resulting in the gain-of-function H155Y 
mutation was strongly correlated with higher levels of post-mastectomy pain and, by contrast, the 
835G>A polymorphism for the loss-of-function R270H mutation was associated with lower levels of 
pain. A significant association of the 835G>A polymorphism with chronic pain was also identified in 
the second cohort of patients with osteoarthritis, an inflammatory condition. 
2.3.4. 489C>T Is a Risk Factor for Childhood Febrile Seizure 
The important role of the P2X7 receptor in inflammatory responses has led to a recent investigation 
of SNPs in the human P2RX7 gene in association with childhood febrile seizures [60]. This study  
has examined 157 febrile seizure patients and 163 control subjects and identified the 489C>T 
polymorphism, which leads to the H155Y mutation, as a risk factor for febrile seizures. Such genetic 
association was further verified by screening febrile seizure patients from the Wellcome Trust Case 
Control Consortium 1958 Birth Cohort. 
2.3.5. 1513A>C Reduces Cardiovascular Risk 
Similarly, the implication of P2X7 receptor-mediated inflammation in atherothrombosis has 
prompted the study of SNPs in the human P2RX7 gene as a cardiovascular risk factor in patients with 
ischemic heart disease and ischemic stroke [61]. The study genotyped SNPs in the P2RX7 gene in 
1244 patients with ischemic heart disease and 5969 individuals with cardiovascular risk factors  
as well as 2488 control subjects, and detailed analysis supports that the 1513A>C polymorphism or  
the loss-of-function E496A mutation may reduce the risk of ischemic heart disease in smokers.  
Such an association was however not obtained in non-smokers. In addition, this study analysed 4138 
ischemic stroke patients and 2528 control subjects, and found that this same NS-SNP may also reduce 
the risk of ischemic stroke. 
2.3.6. 1513A>C in Susceptibility to Tuberculosis (TB) 
Tuberculosis (TB) is a disease that arises from infection by the intracellular pathogen 
Mycobacterium tuberculosis (MTB). MTB predominantly replicates in macrophage cells, which act as 
the main host cells regulating MTB growth and viability. Macrophage cells can kill MTB by producing 
reactive oxygen or nitrogen species [95], and it is known that the P2X7 receptor plays a role in the 
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ATP-induced macrophage killing of MTB [96–98]. It is this role in MTB killing that has driven several 
genetic association studies to investigate the connection between SNPs in the P2RX7 gene and 
susceptibility to TB in various populations. These studies so far have reported inconsistent findings. 
For example, an association of the 1513A>C polymorphism for the E496A mutation with TB was not 
found in an earlier study examining more than 300 Gambian TB patients and 160 control subjects [62]. 
However, the 1513A>C polymorphism has been identified as a risk factor in a separate study that 
analyzed two relatively small cohorts of individuals from Southeast Asia including Vietnam, 
Cambodia, and Laos (86 TB patients and 167 control subjects in the first cohort, and 99 TB patients 
and 102 control subjects in the second cohort) [63]. This NS-SNP has also been found to increase the 
susceptibility to TB in Mexican populations [64], but not in Chinese and Asian Indian subjects [65,66]. 
A meta-analysis study attempted to address the inconsistency of the results obtained from these 
studies, and has concluded significant association of the 1513A>C polymorphism with an increased 
susceptibility to TB [99]. Further analysis of subgroups indicates that this NS-SNP is associated with 
a higher susceptibility to TB in Asian populations but is not a risk factor in Latino or African 
populations [99]. There are a number of factors that may compound these findings, including the allele 
frequency in different ethnic groups, variations in the age of the subjects examined, and TB being 
pulmonary or extrapulmonary. 
2.3.7. 489C>T and 1405A>G Are Potential Factors Increasing Susceptibility to Sepsis 
Sepsis is caused by an overactive inflammatory response to infection. One recent study employing 
the multi-individual array platform, capable of simultaneously identifying variations in the same 
nucleotide in thousands of samples, screened DNA from blood samples taken from 95 patients with 
severe sepsis and 518 control subjects [67]. This study found that the prevalence of two NS-SNPs, 
489C>T and 1405A>G for the H155Y and Q460R mutations respectively, were significantly higher  
in patients suffering from severe sepsis following surgical trauma, implying the presence of these  
NS-SNPs as a potential risk factor for sepsis. Further studies are required to ascertain the association. 
2.3.8. 1068G>A and 1513A>C Alter Susceptibility to Toxoplasmosis 
Toxoplasma gondii is an obligate intracellular parasite, affecting over one third of the human 
population. Despite most infections being asymptomatic and self-limiting, infection acquired during 
pregnancy can lead to congenital toxoplasmosis, resulting in neonatal death or fetal abnormalities. 
Affected infants may display defects in brain and eye functions, and the damage induced by this 
parasite appears to occur at a point when the foetal immunity is poorly developed [100,101]. A study, 
examining SNPs in 149 groups consisting of the child and their parents, has identified the 1068A 
allele, or the 1068G>A polymorphism for the gain-of-function A348T mutation, as a genetic factor 
reducing the susceptibility to the conditions such as intracranial calcification, hydrocephalus and 
retinochoroiditis resulting from Toxoplasma gondii infection in utero [68]. Consistently, a separate 
study has shown that macrophages expressing the loss-of-function E496A mutant P2X7 receptor,  
due to the 1513A>C polymorphism, were less capable of ATP-induced killing of Toxoplasma gondii [69]. 
These findings provide consistent evidence to support an inverse relationship between the P2X7 receptor 
activity and the susceptibility to toxoplasmosis. 
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2.3.9. Multiple NS-SNPs Are Associated with Osteoporosis and Bone Fracture Risk 
Osteoporosis is a progressive skeletal disease causing low bone mass or bone mineral density 
(BMD) and microarchitectural deterioration of bone tissues, predisposing individuals with increased 
bone fragility and fracture risk [102,103]. As introduced above, the P2X7 receptor has a critical role  
in bone formation, metabolism and remodelling, leading to several genetic association studies of SNPs 
in the human P2RX7 gene with increased susceptibility to osteoporosis or risk of bone fracture. These 
studies have identified an association with several NS-SNPs (Table 1). The first study examined  
a cohort of 1764 postmenopausal women and has reported that two NS-SNPs, 1513A>C and 
1729T>A, which cause the loss-of-function E496A and I568N mutations respectively, were associated 
with the vertebral fracture incidence rate over 10 years [70]. The second study investigated a cohort of 
506 post-menopausal women from the Aberdeen Prospective Osteoporosis Screening Study in relation 
to BMD in the lumbar spine [71]. Patients carrying the 946G>A polymorphism for the loss-of-function 
R307Q mutation showed significantly lower lumbar spine BMD, both at baseline and 6–7 years later. 
In addition, a group of subjects carrying multiple NS-SNPs (946G>A, 1096C>G, 1513A>C and 
1929T>A, resulting in the loss-of-function R307Q, T357S, E496A, and I568N mutations respectively) 
manifested approximately 9% reduction in their lumbar spine BMD each year over a period of  
10 years. Another study was published at the same year, which analyzed 12 NS-SNPs with respect to 
the risk of bone fracture in a cohort of 1694 women participating in the Danish Osteoporosis Prevention 
Study [72]. This study, combining measurements of both BMD and fracture incidence at baseline and 
after 10 years, has also found the 946G>A polymorphism to exhibit a clear association with an 
increased rate of bone loss, with the rate of bone loss being 40% higher in patients heterozygous for 
this polymorphism. Furthermore, the 1729T>A polymorphism for the I568N mutation has also been 
associated with an increased rate of bone loss. In contrast, another two NS-SNPs, 1068G>A and 
1405A>G, giving rise to the A348T and Q460R mutations, were linked with an increased BMD and  
a lower rate of vertebral fracture incidence 10 years after menopause. Two further studies have 
examined a Dutch cohort of 690 women and 231 men, and a Danish cohort of 462 osteoporotic men 
and women. In the Dutch cohort, the 1068G>A polymorphism for the gain-of-function A348T 
mutation was found to be associated with higher BMD at the lumbar spine. In contrast, the 474G>A 
and 1513A>C polymorphisms for the loss-of-function G150R and E496A mutations respectively  were 
correlated with decreased BMD in the hip, and the 1405A>G polymorphism for the Q460R mutation 
was linked to a strong increase in the risk of developing osteoporosis [74]. The second recent  
study examined NS-SNPs as a risk factor of bone fracture [73]. The 474G>A polymorphism for  
the loss-of-function G150R mutation is associated with a lower hip BMD in both men and women, 
whereas the 1513A>C polymorphism for the loss-of-function E496A mutation was linked with  
lower lumbar spine BMD in women and lower hip BMD in men. In contrast, the alleles encoding  
the gain-of-function mutations were correlated with lower fracture risk and/or increased BMD.  
The 1405A>G polymorphism for the Q460R mutation was associated with increased BMD in the hips 
of women, and the 1068G>A polymorphism for the A348T mutation was linked to increased BMD 
and lower fracture in men. This is the first study to show segregation of NS-SNPs between  
the genders and suggest that the effects on BMD and bone fracture are mainly driven by the 1068G>A 
polymorphism in men and by the 1405A>G and 1513A>C polymorphisms in women [73].  
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Overall, these genetic studies of NS-SNPs support the concept that increased P2X7 receptor activity 
confers a lower rate of bone loss and a reduced risk of bone fracture in both men and women. 
Consistent with these genetic association studies in humans, the NS-SNP in the mouse p2rx7 gene for 
the loss-of-function P451L mutation has been found to be associated with an increased predisposition 
to osteoporosis [104]. 
Table 1. Disease-associated non-synonymous single nucleotide polymorphisms (NS-SNPs) 
in the P2RX7 gene. 
rs Number Change in Nucleotide  
(Amino Acid) Sequence Implicated Conditions 
rs17525809 370T>V (A76V) Multiple sclerosis [56] 
rs28360447 474G>A (G150R) Osteoporosis [73,74] 
rs208294 489C>T (H155Y) 
Multiple sclerosis [56]; chronic pain [14]; severe sepsis [67]; 
children febrile seizures [60] 
rs7958311 835G>A (R270H) Chronic pain [14] 
rs28360457 946G>A (R307Q) Osteoporosis [71,72] 
rs1718119 1068G>A (A348T) Osteoporosis [72–74]; anxiety disorder [54]; toxoplasmosis [68] 
rs2230911 1096C>G (T357S) Osteoporosis [71] 
rs2230912 1405A>G (Q460R) 
Osteoporosis [72–74]; severe sepsis [67]; bipolar disorders and 
major depressive disorders [52,53,55,81] (but see [82,83]) † 
rs3751143 1513A>C (E496A) 
Osteoporosis [70–74]; tuberculosis [63,64,99];  
cardiovascular risks [61] 
rs1653624 1729T>A (I568N) Osteoporosis [70–72] 
†, association with bipolar disorders and major depressive disorders is not supported by studies shown in brackets. 
3. NS-SNP Mutational Effects on Receptor Function 
The seven mammalian P2X receptor subunits vary in length, with the human P2X receptor subunits 
ranging from 377 amino acid residues in the P2X6 receptor to 595 residues in the P2X7 receptor [8]. 
However, all of them have the same membrane topology, containing a large extracellular domain,  
two transmembrane domains (TM1 and TM2) and intracellular C- and N-termini (Figures 1–4).  
While the extracellular and transmembrane domains show strong amino acid sequence conservation 
and are similar in length, the intracellular domains are less conserved and variable in length, with  
the P2X7 receptor subunit having a much longer C-terminus. The crystal structures of the zebrafish 
P2X4 receptor have been determined in the closed [105] and ATP-bound open states [106], 
representing the most recent milestone in P2X receptor research. Despite the lack of the intracellular 
domains, these structures have been invaluable in understanding ATP binding and channel gating [107]. 
The high sequence similarity between the zebrafish P2X4 receptor and the mammalian P2X  
receptors enables homology modelling of the latter receptors. Such structural models have provided  
the structural framework for more accurate interpretations of the site-directed mutagenesis data 
accumulated over the past decade [107–109] and provide exciting opportunities to define the  
structure-function relationships of the mammalian P2X receptors in greater detail [107] and design 
small molecular chemicals for therapeutics. As illustrated in Figure 1, the human P2X7 receptor,  
as with other P2X receptors, assumes a “chalice-like” structure, in which three subunits are intertwined 
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around each other in a three-fold symmetric manner running perpendicularly to the cell membrane and 
the six α-helical transmembrane domains, two from each of the three subunits, form the central 
aqueous ion-conducting pore. The overall shape of each subunit has been suggested to resemble that of 
a leaping dolphin (Figures 2A–4A). 
The mutations resulting from NS-SNPs have been examined in terms of their effects on the  
Ca2+-permeable cationic channel function by measuring agonist-induced Ca2+ influx or currents and on 
the ability to induce large pore formation by monitoring fluorescent dye uptake. In this section we will 
discuss such mutational effects, focusing on those arising from the disease-associated NS-SNPs 
described above. Their locations in the structural homology models are shown for the human P2X2 
receptor (Figure 2A), human P2X4 receptor (Figure 3A), and human P2X7 receptor except for  
the mutations (Glu460, Glu496 and Ile568) in the C-terminus of the human P2X7 receptor (Figure 4A) as 
the structural information of the intracellular domains is still unavailable. 
Figure 1. Structural homology models of the trimeric human P2X7 receptor. (Left) closed 
state; and (right) ATP-bound open state, viewed parallel to the plasma membrane (top) or 
the extracellular side (bottom). The three subunits are denoted in different colours, and the 
three bound ATP molecules are highlighted in spheres. 
 
3.1. V60L and the Human P2X2 Receptor 
The effect of the V60L mutation has been examined in several heterologous expression systems. 
When expressed in HEK293 cells, the human V60L mutant P2X2 receptor failed to mediate  
detectable ATP-induced currents, in contrast with the strong currents conducted by the wild-type 
Extracellular
+ ATP
Int. J. Mol. Sci. 2014, 15 13355 
 
 
receptor [25]. Expression of the wild-type P2X2 receptor in MDCK-II cells conferred strong ATP-induced 
FM1-43 fluorescent dye uptake but expression of the mutant V60L receptor resulted in no such dye 
uptake. Cells co-expressing the wild-type and mutant P2X2 subunits exhibited ATP-evoked FM1-43 
uptake but the response was reduced by approximately 60% [25]. The GFP-tagged wild-type or V60L 
mutant P2X2 proteins, when expressed in the explant cultures of neonatal rat organ of Corti and 
vestibular tissues, showed identical localization and, as anticipated, appeared in the apical membranes 
of hair cells in the organ of Corti [25]. These results suggest that the V60L mutation impairs the 
function of the receptor rather than its expression or subcellular localization. Valine at this position is 
highly conserved within the mammalian P2X2 receptors and located at the outer end of TM1 (Figure 2B). 
Cysteine substitution of the corresponding residue (Val48) in the rat P2X2 receptor had minimal effect 
on receptor function [110]. Simultaneous cysteine substitution of Val48 and Ile328 in the outer end of 
TM2 resulted in the spontaneous formation of a disulphide bond which prevented the channel opening, 
suggesting close vicinity of these two positions and substantial relative movement of the regions 
surrounding them during receptor activation [110]. This notion has been elegantly illustrated in 
structural models, which show the two positions to juxtapose very closely in the closed state but move 
far apart in the open state (Figure 2B). The structural models offer one possible interpretation of the 
loss of function by the V60L mutation; the larger side-chain of leucine introduced at this position may 
impede the relative movement of TM1 and TM2 (Figure 2B), the conformational changes required for 
channel opening. 
Figure 2. Structural homology models of the human P2X2 receptor. (A) The dolphin-like 
structure of a single receptor subunit in the closed state is shown with distinctive body 
parts in different colours, and Val60 in the extracellular end of TM1 and Gly353 in the 
intracellular half of TM2 are highlighted; (B) Changes in the distance between Val60 and 
Ile339 (left) and structural differences introduced by the V60L in the closed (top) and open 
states (bottom) viewed from the extracellular side of the membrane; and (C) Structural 
differences introduced by mutating Gly353 (top) to arginine (bottom) in the open state 
viewed from the cytoplasmic side of the membrane. TM: transmembrane domains. 
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3.2. G353R and the Human P2X2 Receptor 
Gly353 is located in the intracellular half of TM2 (Figure 2A,C). This residue is completely conserved  
in the mammalian P2X receptor family, corresponding to Gly342 in the rat P2X2 receptor [111]. A previous 
study which combined sited-directed mutagenesis and structural modelling suggests that  
in the rat P2X2 receptor the residues between Asn333 and Asp349 form the narrowest part or  
the physical gate of the ion-permeating pore that occludes the ion permeation in the closed state and 
Gly342 is thus part of the intracellular pore [111]. The mutational effect on the human P2X receptor 
function has not been characterized so far. It has been proposed based on structural modelling that the 
mutation of Gly353 to arginine with a positively-charged and long side-chain may introduce structural 
distortions and anomalous interactions with the membrane lipids [27], but the supporting evidence  
still awaits. Nonetheless, Gly342 in the rat P2X2 receptor has been examined in considerable detail. 
Expression of the G342C mutant receptor resulted in small spontaneous currents, as well as  
ATP-evoked currents [111,112]. The P2X2 receptor carrying substitution with alanine, aspartate, 
serine, threonine, tryptophan, or phenylalanine exhibited normal channel unitary conductance, which 
was substantially reduced by the G342K mutation [111]. Introduction of the G353R mutation in the 
human P2X2 receptor may confer a larger inhibitory effect on the channel conductance. 
3.3. Y315C and the Human P2X4 Receptor 
The effects of the Y315C mutation on the human P2X4 receptor have been characterized after 
heterologous expression in HEK293 cells using patch-clamp recording [34]. The Y315C mutation 
impaired receptor function by conferring 10-fold reduction in the maximal current amplitude and  
>30-fold reduction in the ATP sensitivity. Replacement of Tyr315 with serine carrying an OH group 
instead of a SH group in cysteine resulted in a similar reduction in the ATP sensitivity with no 
significant change in the maximal current amplitude. Treatment with the reducing agent dithiothreitol 
had no effect on ATP-induced currents mediated by the wild-type or Y315S mutant receptor,  
but increased the currents by the Y315C mutant receptor with the maximal current amplitude similar to 
that at the wild-type and Y315S mutant receptors. These results suggest that cysteine introduced by  
the Y315C mutation forms aberrant disulphide bonds with cysteine residues present in the extracellular 
domain and that such disulphide bonds alter the tertiary structure of the P2X4 receptor and thereby 
prevent full receptor activation. Structural models of the human P2X4 receptor based on the crystal 
structure of the zebrafish P2X4 receptor in the closed and open states [105,106] show that position 315 
is in close vicinity to the inter-subunit ATP-binding site (Figure 3). Furthermore, molecular docking 
studies suggest that the replacement of tyrosine with cysteine or serine impairs ATP binding [34]. 
3.4. A76V and the Human P2X7 Receptor 
The literature contains a number of studies comparing the effects of either the A76V or V76A 
mutation with their respective parental “wild-type” human P2X7 receptor carrying alanine or valine  
at position 76 [56,113,114]. HEK293 cells expressing the A76V mutant receptor exhibited higher  
Ca2+ influx, larger whole-cell currents and an increased rate of ethidium dye uptake when compared  
to cells expressing the wild-type P2X7 receptor carrying Ala76 upon stimulation with ATP [56].  
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Conversely, ATP-evoked currents and ethidium dye uptake were significantly reduced in HEK293 
cells expressing the V76A mutant receptor compared to cells expressing the wild-type receptor 
harbouring Val76, with no major change in the ATP sensitivity [113,114]. Therefore, these studies have 
drawn a consistent conclusion that the receptors having valine at position 76 show greater functional 
activity than the receptors carrying alanine. Position 76 is located within the “upper body” region of 
the extracellular domain in the structural models (Figure 4B) and in the middle of a loop that differs 
between the P2X7 receptor and the other P2X receptors, including the P2X2 and P2X4 receptors  
(c.f., Figures 2A–4A). The change from alanine to valine increases the size of the side-chain  
(Figure 4B). Comparison of the structures of the zebrafish P2X4 receptor in the closed and open  
states indicates a lack of substantial conformational change in the upper body during receptor  
activation [106] and thus the homology modelling of the human P2X7 receptor does not provide 
obvious clues as to how the A76V mutation increases receptor function. 
Figure 3. Structural homology models of the human P2X4 receptor. (A) the dolphin-shaped 
structure of a single receptor subunit in the closed state shown with distinctive body parts in 
different colours (the same colour scheme used in Figure 2A for the human P2X2 receptor 
subunit) and the location of Tyr315 highlighted; and (B) views of Tyr315 (orange; top) and 
Cys315 (magenta, bottom) in the close proximity to the ATP-binding site in the open state. 
 
3.5. G150R and the Human P2X7 Receptor 
Gly150 is highly conserved across all members of the P2X family [8], suggesting a vital role for this 
residue. Monocytes endogenously expressing the G150R mutant human P2X7 receptor exhibited strongly 
reduced dye uptake or pore formation as compared to cells expressing the wild-type receptor [115]. 
Heterologous expression of this mutant P2X7 receptor in HEK293 cells resulted in no detectable 
current and dye uptake in response to ATP [115]. This residue is situated on the top of the head 
domain, towards the ‘beak’ part, which undergoes little movement during ATP-induced transition from 
the closed to open state (Figure 4C). Homology modelling of the human P2X7 receptor thus offers no 
straightforward interpretation for the loss of receptor function. Nonetheless, arginine has a large and 
positively-charged side-chain and the G150R mutation may prevent the strucutural flexibility that is 
required for conformational changes in the adjacent parts [116] (Figure 4C). 
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Figure 4. Structural homology models of the human P2X7 receptor. (A) the dolphin-shaped 
structure of a single receptor subunit in the closed state is shown with distinctive body 
parts in different colours (the same colour scheme used in Figure 2A and Figure 3A for the 
human P2X2 and P2X4 receptor subunits) and location of the residues to be mutated by 
disease-associated NS-SNPs are highlighted; (B–F) structural differences introduced by the 
V76A (B), G150R (C), H155Y (D), R270H (E), and A348T mutation (F) in the closed (top) 
and open state (bottom). The original residues are shown in orange and the substituted 
residues in magenta in (B–E). (F) is viewed from the cytoplasmic side of the membrane. 
 
3.6. H155Y and the Human P2X7 Receptor 
While the 489C>T polymorphism for the H155Y mutation is associated with chronic pain, but not 
with CLL, systemic lupus erythematosus and rheumatoid arthritis, lymphocytes from patients with 
such conditions expressing the H155Y mutant receptor showed higher Ca2+ influx in response to 
extracellular ATP [58,117]. Such gain of function was consistently observed in heterologous 
expression cells expressing the mutant receptor. There were significantly greater ATP-induced Ca2+ 
influx and ethidium uptake in HEK293 cells expressing the H155Y mutant receptor [118]. The H155Y 
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mutation also increased agonist-induced currents mediated by the human P2X7 receptor expressed in 
HEK293 cells [113,119]. The increases in receptor-mediated responses were not related to an effect on 
the ATP sensitivity, consistent with the location of His155 in the head domain far away from the  
ATP-binding site (Figure 4D). A more systematic study of the effects of changing His155 to residues 
with different side-chain properties on the P2X7 receptor function and cell surface expression has led 
to the conclusion that the gain of function accompanying the H155Y mutation predominantly results 
from a higher level of receptor expression on the cell surface [119]. A recent study suggests that the 
mutation may increase total protein expression of the P2X7 receptor [120]. 
3.7. R270H and the Human P2X7 Receptor 
The human P2X7 clone that is widely used in heterologous expression studies encodes a receptor 
containing histidine instead of arginine at position 270. HEK293 cells expressing the H270R mutant 
receptor showed larger ATP-induced ethidium uptake than cells expressing the wild-type receptor [114]. 
Thus, the gain of function resulting from the H270R mutation suggests by inference that the human 
P2X7 receptor carrying His270 or the R270H mutation is hypofunctional compared to the wild-type 
receptor carrying Arg270. A recent study of the canine P2X7 receptor has shown the R270C mutant 
receptor was non-functional, highlighting the functional importance of Arg270 [121]. The residue at 
position 270 is part of a loop region in the lower body of the extracellular domain which undergoes some 
conformational change during receptor activation (Figure 4E), but such information is insufficient to 
explain how the aforementioned mutations alter the receptor function. 
3.8. A348T and the Human P2X7 Receptor 
The A348T mutation was initially reported to decrease the functional activity of the human P2X7 
receptor endogenously expressed in lymphocytes and heterologously expressed in HEK293 cells [117]. 
Subsequent studies have proved the contrary. Expression of the A348T mutant receptor in HEK293 cells 
resulted in significantly greater ATP-induced currents or dye uptake than when the wild-type human 
P2X7 receptor was expressed [113,119]. The mutation did not, however, have an effect on the ATP 
sensitivity. The equivalent residue in the rat P2X7 receptor is threonine and the introduction of the 
T348A mutation significantly reduced ATP-induced currents without altering the ATP sensitivity [119]. 
Immunofluorescent confocal imaging and Western blotting analyses indicate that the A348T mutation 
in the human P2X7 receptor and the reciprocal T384A mutation in the rat P2X7 receptor had no effect 
on the total and cell surface expression of the receptors [119], although a recent study suggests that  
the A348T mutation may also increase total protein expression of the human P2X7 receptor [120]. 
Homology modelling of the P2X7 receptors has revealed that this residue is located in TM2 as part of 
the intracellular pore and immediately adjacent to the physical gate (Figure 4F). There is evidence 
suggesting that the intracellular pore may narrow during channel opening [122]. As such it is likely 
that Ala348 plays a role in modulating channel opening, ion permeation or both. This notion is highly 
consistent with the inverse relationship between the size of the amino acid residue introduced at this 
position and the effect on the ATP-induced current amplitude; changes to residues with smaller  
side-chains resulted in larger currents, whereas changes to residues with much larger side-chains led to 
smaller currents [119]. 
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3.9. Q460R and the Human P2X7 Receptor 
The glutamine residue at position 460 is located in the intracellular C-terminus and is highly 
conserved across the mammalian P2X7 receptors. The ATP-induced currents in HEK293 cells 
expressing the Q460R mutant receptor were not statistically different from those in cells expressing  
the wild-type receptor [113,117]. Studies have reported that the Q460R mutation either had no  
effect [113,117], a slight increase [115] or a modest but significant reduction [114] in terms of the 
ability of the receptor to induce large pore formation or dye uptake. The findings that the Q460R 
mutation does not significantly affect P2X7 receptor function are perhaps rather unexpected, given  
the association of the 1405A>G polymorphism for this mutation with several disease conditions  
(Table 1). However, this NS-SNP has been found to be co-inherited with other NS-SNPs that confer  
gain-of-function mutations, such as H155Y, H270R, and A468T [114]. Further studies are thus 
required to examine the possibility that the disease association is related to the NS-SNPs that are  
co-inherited with the 1405A>G polymorphism. 
3.10. E496A and the Human P2X7 Receptor 
The E496A mutation resulting from the 1315A>C polymorphism is located in the intracellular  
C-terminal tail of the P2X7 receptor. This mutation has been examined in several studies and the 
literature contains conflicting results. An early immunofluorescent confocal microscopy study revealed 
similar cell surface expression for the wild-type receptor and the E496A mutant receptor endogenously 
expressed in human leukocytes [123]. However, further studies which made use of flow cytometry 
assays to determine ethidium dye uptake and Ba2+ influx in these cells showed that the mutant receptor 
was non-functional when expressed at low density but regained the normal functionality when 
expressed at high density [117,123]. HEK293 cells expressing the mutant receptor displayed very  
low ATP-dependent ethidium uptake [117], consistently supporting the idea that the large pore 
functionality of the P2X7 receptor is impaired. A separate study showed very similar ion channel 
functional properties as evidenced by the lack of significant difference in the ATP-induced current 
amplitude, channel activation and deactivation kinetics, and permeation between the wild-type and 
E496A mutant receptors expressed in Xenopus oocytes and HEK293 cells [124]. This study did not 
examine the large pore functionality but, by combining with the previous study [123], has concluded 
that Glu496 plays a determinant role in large pore formation but not in ion channel functional properties 
of the human P2X7 receptor. A subsequent study compared the ATP-induced currents and dye  
uptake mediated by the wild-type and E496A mutant receptors expressed in HEK293 cells, and  
the results clearly indicate that the E496A mutation impairs both ion channel and large pore 
functionalities [113]. 
The E496A mutation has been studied for its effect on the P2X7-dependent release of IL-1β. An 
earlier study showed that ATP-induced IL-1β release was attenuated in human monocytes expressing 
the E496A receptor upon treatment with a high concentration of ATP for short durations [125].  
A recent study has used whole blood samples from patients with bone fractures carrying the E496A 
mutant receptor and from control subjects expressing the wild-type receptor, and found IL-1β release 
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induced by prolonged exposure to ATP was in fact increased in cells expressing the E496A mutant 
receptor [126]. The exact cause for the discrepancy in such results remains to be established. 
3.11. I568N and the Human P2X7 Receptor 
The Ile568 residue lies in the distal tail of the intracellular C-terminus and is highly conserved 
among the mammalian P2X7 receptors. Human lymphocytes heterozygous for the I568N mutation 
showed lower ATP-induced Rb+ and Ba2+ flux (reflective of K+ and Ca2+ permeation respectively),  
due to reduced cell surface expression [127]. However, HEK293 cells expressing the P2X7 receptor 
containing this mutation exhibited no detectable ATP-evoked current and dye uptake [113], consistent 
with Ile568 being part of the trafficking motif that is composed of residues 551–581 and is important in 
membrane trafficking of the P2X7 receptor [128]. 
4. Concluding Remarks 
Studies over the past decades, mainly using rodent animals, cells and models of diseases, have 
revealed an important role for P2X receptors in mediating extracellular ATP signalling in a wide range 
of physiological and pathological processes. The P2RX genes encoding the human P2X receptors are 
rich in SNPs. As highlighted above, an increasing number of NS-SNPs have shown to be associated 
with diseases and significantly influence the receptor activity by altering receptor expression and/or 
functional properties. These findings, taken together, have provided direct evidence to support a role of 
the human P2X receptors in health and disease. The evidence from these studies is compelling for 
certain diseases, but additional well-designed and large-scale genetic association studies are required to 
ascertain the role for the human P2X receptors in many other conditions. The study of NS-SNPs will 
continue to help us to advance the understanding of several aspects of the P2X receptors. Firstly, 
studies of SNPs in the P2RX genes can yield direct evidence for the role of human P2X receptors in the 
aetiology of a particular disease, such as the P2X2 receptor in hearing loss, or a group of diseases such 
as the P2X7 receptor in several inflammatory conditions. Secondly, disease-associated NS-SNPs could 
be used as diagnosis biomarkers to formulate preventive measurements, for example to reduce the risk 
of hearing loss and bone fracture and also to develop personalized treatments for osteoporosis and 
chronic pain. Thirdly, characterizations of the mutations caused by the disease-associated NS-SNP will 
aid us to gain a better understanding of the disease mechanisms and structure-function relationships of 
human P2X receptors. Finally, an improved delineation of the structure-function relationships of the 
human P2X receptors is critical for drug discovery because there are striking differences in functional 
and pharmacological properties between the human and rodent P2X receptors, as shown for the P2X2, 
P2X4, P2X5, and P2X7 receptors (e.g., [29,129–135]). 
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